ADMA (asymmetric dimethylarginine) , NTproBNP (N-terminal pro b-type natriuretic peptide), IL-6 (Interleukin 6), Adiponectina, Leptine, Syndecan, Resistin
Diagnostic TestADMA, NTproBNP, IL-6, Adiponectina, Leptine, Syndecan, Resistin
NCT Number: NCT03377465
A stroke is the second cause of deaths after heart attack, one of the most important causes of malfunction as far as adults are concerned and the second as for the frequency cause of dementia. In spite of a possibility of the therapy of stroke ( tissue plasminogen activator) and recognized most of risk factors there is expected that incidence rate on stroke connected with ageing of the society will be growing. It will cause medical and social consequences.
There are many of potential causes of cardiac strokes, which are not entirely examined.
More over many cryptogenic strokes are presumed to have an embolic etiology, and the frequent cause of these kind of strokes at young age is probably the mechanism of paradoxical embolism through patent foramen ovale.
As far as the investigators are concerned, at present there is lack of any recommendations for these scientific hypothesis.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
A stroke is the second cause of deaths after heart attack, one of the most important causes of malfunction as far as adults are concerned and the second as for the frequency cause of dementia. In spite of a possibility of the therapy of stroke ( tissue plasminogen activator) and recognized most of risk factors there is expected that incidence rate on stroke connected with ageing of the society will be growing. It will cause medical and social consequences.
The risk factors of stroke can be divided into alterable and not alterable. Importantly, the not alterable factors are: age, sex, race and genetic factors. After the age of 55 the risk of stroke grows twice in every decade of life. Moreover, it was alleged that incidence rate on stroke is more frequent at women than at men. At the black race the incidence rate on stroke is twice more frequent than at white race.
Well- known are also genetic syndromes connected with strokes like s. MELAS or CADASIL.
Well- known alterable factors are:
Cardiogenic stroke is a stroke caused by embolic material, which was created in cardiac cavities or on cardiac valves. They comprised 11% of all strokes and 25% of ischemic strokes. Additionally, among patients over 80 years old cardiac causes are responsible for even 40% of all ischemic strokes and half of cardiogenic strokes is caused of atrial fibrillation. Among young people (below 45 years old) about 50% of strokes are cardiogenic and are connected with paradoxical embolism at patients with patent foramen ovale.
Furthermore, cardiac- brain embolism is a result of:
There are many of potential causes of cardiac strokes, which are not entirely examined as for example:
As far as the investigators are concerned, at present there is lack of any recommendations for these scientific hypothesis.
Available data suggest that in the comparison with atherosclerosis and lacunar strokes cardiogenic strokes characterize with high mortality ranging of 27%. Also the risk of relapse is higher than in strokes of other etiology.
Nevertheless, unfortunately, in spite of wide diagnostics at about 25-30% of patients with ischemic stroke the cause is unknown. This kind of stroke is called cryptogenic stroke or stroke with undefined etiology.
They constitute almost half of all ischemic stroke at young patients (below 55 years old). Many cryptogenic strokes are presumed to have an embolic etiology, and the frequent cause of these kind of strokes at young age is probably the mechanism of paradoxical embolism through patent foramen ovale.
To conclude, currently there aren't researches defining recommendations for long- lasting treatment patients with rare causes of strokes.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
ADMA, NTproBNP, IL-6, Adiponectina, Leptine, Syndecan, Resistin
Time frame: 24 months
CRP (C reactive protein)
Time frame: 24 months
IL-6 (interleukin 6)
Time frame: 24 months
ADMA (asymmetric dimethylarginine)
Time frame: 24 months
NTproB (N-terminal pro b-type natriuretic peptide)
Time frame: 24 months
Adiponectin
Time frame: 24 months
Leptine
Time frame: 24 months
Resistin
Time frame: 24 months
Syndecan
Medical University of Lodz
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07479147
Brain Diseases, Cardiovascular Abnormalities
Taichung, Taiwan
View Trial DetailsNCT04604015
Brain Diseases, Brain Ischemia
Phoenix, Arizona, United States
View Trial DetailsNCT03107637
Brain Diseases, Cardiovascular Diseases
Paris, France
View Trial DetailsNCT07194811
Arrhythmias, Cardiac, Atrial Fibrillation
Oslo, Lørenskog/Akershus, Norway
View Trial Details